. 2019 Nov 14;36(12):180. doi: 10.1007/s11095-019-2707-3

Table IV.

Scaled Average Bioequivalence (SABE) Assessment between the Products Used in Study 1 (ACV-US versus ACV-UK) and in Study 2 (ACV-AT versus ACV-US) for a Bioequivalence Margin (m). Products are Considered Bioequivalent if the Upper Bound on the Scaled Average Confidence Interval (SCl_UB) < 0 and Geometric Mean Ratio (GMR) is within the Limit [1/m, m]

Study 1	Uptake				Clearance
	s_WR	SCI_UB		GMR	s_WR	SCI_UB		GMR
	s_WR	m = 1.25	m = 1.33	GMR	s_WR	m = 1.25	m = 1.33	GMR
US-C+/US-Ref	0.599	−0.125	−0.235	0.87	0.718	−0.217	−0.372	0.94
UK-Test/US-Ref	0.599	0.200	0.065	0.61	0.718	0.317	0.108	0.58
UK-Test/US-C+	0.321	0.216	0.168	0.70	0.458	0.578	0.466	0.61
Study 2	Uptake				Clearance
	s_WR	SCI_UB		GWR	s_WR	SCI_UB		GMR
	s_WR	m = 1.25	m = 1.33	GWR	s_WR	m = 1.25	m = 1.33	GMR
AT-C+/AT-Ref	0.695	−0.177	−0.328	1.12	0.426	0.010^a	−0.062	0.86
AT-Ref/US-Test	0.463	0.393	0.295	1.61	0.317	0.787	0.737	1.99
AT-C+/US-Test	0.463	0.658	0.555	1.81	0.317	0.453	0.404	1.71